ArticleBritish journal of cancer2014
Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- High-Grade Urothelial Carcinoma with Clear-Cell (Glycogen-Rich) Features and Divergent Trophoblastic Differentiation: A Histopathological Case Report.Reports (MDPI) · 2025Article
- [Elevation of β-subunit of human chorionic gonadotropin in urological patients-not always a germ cell tumor].Urologie (Heidelberg, Germany) · 2025Review
- A Case of Renal Metastasis of Urothelial Carcinoma With Trophoblastic Differentiation Successfully Treated With Robot-Assisted Partial Nephrectomy.IJU case reports · 2025Article
- Chorionic Gonadotropin Beta 7 is a marker of immune evasion in cancer.bioRxiv : the preprint server for biology · 2025Article
- Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.Urologic oncology · 2024Review
- Aberrant trophoblastic differentiation in human cancer: An emerging novel therapeutic target (Review).Oncology reports · 2024Review
- Beta-human chorionic gonadotropin, carbohydrate antigen 19-9, cancer antigen 125, and carcinoembryonic antigen as prognostic and predictive biological markers in bladder cancer.Frontiers in oncology · 2024Article
- Recent Advances in the Classification of Bladder Cancer - Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors.Bladder cancer (Amsterdam, Netherlands) · 2023Review
- Progesterone limits the tumor-promoting effects of the beta-subunit of human chorionic gonadotropin via non-nuclear receptors.iScience · 2022Article
- Urothelial carcinoma of the prostate with raised β-hCG levels: a case report.Journal of medical case reports · 2022Article
- Unusual Faces of Bladder Cancer.Cancers · 2020Review
- Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review.Translational cancer research · 2020Review
- Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.Current urology reports · 2019Review
- CGB5 expression is independently associated with poor overall survival and recurrence-free survival in patients with advanced gastric cancer.Cancer medicine · 2018Article
- Human Chorionic Gonadotropin and Breast Cancer.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSerum total human chorionic gonadotrophin β subunit (hCGβ) level might have prognostic value in urothelial transitional cell carcinoma (TCC) but has not been investigated for independence from other prognostic variables.
methodsWe utilised a clinical database of patients receiving chemotherapy between 2005 and 2011 for urothelial TCC and an independent cohort of radical cystectomy patients for validation purposes. Prognostic variables were tested by univariate Kaplan-Meier analyses and log-rank tests. Statistically significant variables were then assessed by multivariate Cox regression. Total hCGβ level was dichotomised at < vs ≥2 IU l(-1).
resultsA total of 235 chemotherapy patients were eligible. For neoadjuvant chemotherapy, established prognostic factors including low ECOG performance status, normal haemoglobin, lower T stage and suitability for cisplatin-based chemotherapy were associated with favourable survival in univariate analyses. In addition, low hCGβ level was favourable when assessed either before (median survival not reached vs 1.86 years, P=0.001) or on completion of chemotherapy (4.27 vs 0.42 years, P=0.000002). This was confirmed in multivariate analyses and in patients receiving first- and second-line palliative chemotherapy, and in a radical cystectomy validation set.
conclusionsSerum total hCGβ level is an independent prognostic factor in patients receiving chemotherapy for urothelial TCC in both curative and palliative settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.